-
Je něco špatně v tomto záznamu ?
Case-Control Study: Smoking History Affects the Production of Tumor Antigen-Specific Antibodies NY-ESO-1 in Patients with Lung Cancer in Comparison with Cancer Disease-Free Group
D. Myšíková, I. Adkins, N. Hradilová, O. Palata, J. Šimonek, J. Pozniak, J. Kolařík, A. Skallová-Fialová, R. Špíšek, R. Lischke,
Jazyk angličtina Země Spojené státy americké
Typ dokumentu srovnávací studie, časopisecké články, práce podpořená grantem
- MeSH
- adenokarcinom krev etiologie patologie MeSH
- antigeny nádorové krev imunologie MeSH
- dospělí MeSH
- kouření škodlivé účinky MeSH
- lidé středního věku MeSH
- lidé MeSH
- membránové proteiny krev imunologie MeSH
- nádorové biomarkery krev MeSH
- nádorové proteiny krev MeSH
- nádory plic krev etiologie patologie MeSH
- následné studie MeSH
- nemalobuněčný karcinom plic krev etiologie patologie MeSH
- prognóza MeSH
- prospektivní studie MeSH
- receptor erbB-2 krev MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- spinocelulární karcinom krev etiologie patologie MeSH
- staging nádorů MeSH
- studie případů a kontrol MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- srovnávací studie MeSH
INTRODUCTION: Lung cancer is the leading cause of cancer mortality worldwide; therefore, understanding the biological or clinical role of tumor-associated antigens and autoantibodies is of eminent interest for designing antitumor immunotherapeutic strategies. METHODS: Here we prospectively analyzed the serum frequencies of New York esophageal squamous cell carcinoma 1 (NY-ESO-1), human epidermal growth factor 2/neu, and melanoma-associated antigen A4 (MAGE-A4) antibodies and expression of the corresponding antigens in tumors of 121 patients with NSCLC undergoing an operation without prior neoadjuvant chemotherapy and compared them with those in 57 control age-matched patients with no history of a malignant disease. RESULTS: We found that only antibodies specific for NY-ESO-1 (19.8% [n = 24 of 121]) were significantly increased in the group of patients with NSCLC compared with in the controls. NY-ESO-1 seropositivity was significantly positively associated with an active smoking history in patients with NSCLC but not in smokers from the control group. In tumors, the frequency of NY-ESO-1 mRNA expression was 6.3% (in four of 64 patients), the frequency of human epidermal growth factor 2/neu (HER 2/neu) expression was 11.9% (five of 42), and the frequency of MAGE-A4 expression was 35.1% (20 of 57). MAGE-A4 expression in tumors correlated with smoking status and male sex in patients with NSCLC. Patients with squamous cell carcinoma displayed higher expression of NY-ESO-1 and MAGE-A4 in tumors than did patients with adenocarcinoma. On the other hand, 94.7% of nonsmoking patients in our study had adenocarcinoma (of whom 73.7% were women). CONCLUSION: These results confirm the reported high immunogenicity of NY-ESO-1 and suggest that a smoking-induced chronic inflammatory state might potentiate the development of NY-ESO-1-specific immune responses. Moreover, smoking might contribute to the expression of other cancer/testis antigens such as MAGE-A4 at early stages of NSCLC development.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc18016951
- 003
- CZ-PrNML
- 005
- 20180518130239.0
- 007
- ta
- 008
- 180515s2017 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.jtho.2016.09.136 $2 doi
- 035 __
- $a (PubMed)27793776
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Myšíková, Dagmar $u Thoracic and Lung Transplantation Division, Third Department of Surgery, First Faculty of Medicine, Charles University in Prague and University Hospital Motol, Prague, Czech Republic. Electronic address: dagmar.mysikova@fnmotol.cz.
- 245 10
- $a Case-Control Study: Smoking History Affects the Production of Tumor Antigen-Specific Antibodies NY-ESO-1 in Patients with Lung Cancer in Comparison with Cancer Disease-Free Group / $c D. Myšíková, I. Adkins, N. Hradilová, O. Palata, J. Šimonek, J. Pozniak, J. Kolařík, A. Skallová-Fialová, R. Špíšek, R. Lischke,
- 520 9_
- $a INTRODUCTION: Lung cancer is the leading cause of cancer mortality worldwide; therefore, understanding the biological or clinical role of tumor-associated antigens and autoantibodies is of eminent interest for designing antitumor immunotherapeutic strategies. METHODS: Here we prospectively analyzed the serum frequencies of New York esophageal squamous cell carcinoma 1 (NY-ESO-1), human epidermal growth factor 2/neu, and melanoma-associated antigen A4 (MAGE-A4) antibodies and expression of the corresponding antigens in tumors of 121 patients with NSCLC undergoing an operation without prior neoadjuvant chemotherapy and compared them with those in 57 control age-matched patients with no history of a malignant disease. RESULTS: We found that only antibodies specific for NY-ESO-1 (19.8% [n = 24 of 121]) were significantly increased in the group of patients with NSCLC compared with in the controls. NY-ESO-1 seropositivity was significantly positively associated with an active smoking history in patients with NSCLC but not in smokers from the control group. In tumors, the frequency of NY-ESO-1 mRNA expression was 6.3% (in four of 64 patients), the frequency of human epidermal growth factor 2/neu (HER 2/neu) expression was 11.9% (five of 42), and the frequency of MAGE-A4 expression was 35.1% (20 of 57). MAGE-A4 expression in tumors correlated with smoking status and male sex in patients with NSCLC. Patients with squamous cell carcinoma displayed higher expression of NY-ESO-1 and MAGE-A4 in tumors than did patients with adenocarcinoma. On the other hand, 94.7% of nonsmoking patients in our study had adenocarcinoma (of whom 73.7% were women). CONCLUSION: These results confirm the reported high immunogenicity of NY-ESO-1 and suggest that a smoking-induced chronic inflammatory state might potentiate the development of NY-ESO-1-specific immune responses. Moreover, smoking might contribute to the expression of other cancer/testis antigens such as MAGE-A4 at early stages of NSCLC development.
- 650 _2
- $a adenokarcinom $x krev $x etiologie $x patologie $7 D000230
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a senioři nad 80 let $7 D000369
- 650 _2
- $a antigeny nádorové $x krev $x imunologie $7 D000951
- 650 _2
- $a nádorové biomarkery $x krev $7 D014408
- 650 _2
- $a nemalobuněčný karcinom plic $x krev $x etiologie $x patologie $7 D002289
- 650 _2
- $a spinocelulární karcinom $x krev $x etiologie $x patologie $7 D002294
- 650 _2
- $a studie případů a kontrol $7 D016022
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a následné studie $7 D005500
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a nádory plic $x krev $x etiologie $x patologie $7 D008175
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a membránové proteiny $x krev $x imunologie $7 D008565
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a nádorové proteiny $x krev $7 D009363
- 650 _2
- $a staging nádorů $7 D009367
- 650 _2
- $a prognóza $7 D011379
- 650 _2
- $a prospektivní studie $7 D011446
- 650 _2
- $a receptor erbB-2 $x krev $7 D018719
- 650 _2
- $a kouření $x škodlivé účinky $7 D012907
- 655 _2
- $a srovnávací studie $7 D003160
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Adkins, Irena $u Department of Immunology, Second Faculty of Medicine and University Hospital Motol, Charles University, Prague, Czech Republic; Sotio a.s., Prague, Czech Republic.
- 700 1_
- $a Hradilová, Nad'a $u Department of Immunology, Second Faculty of Medicine and University Hospital Motol, Charles University, Prague, Czech Republic; Sotio a.s., Prague, Czech Republic.
- 700 1_
- $a Palata, Ondřej $u Department of Immunology, Second Faculty of Medicine and University Hospital Motol, Charles University, Prague, Czech Republic; Sotio a.s., Prague, Czech Republic.
- 700 1_
- $a Šimonek, Jan $u Thoracic and Lung Transplantation Division, Third Department of Surgery, First Faculty of Medicine, Charles University in Prague and University Hospital Motol, Prague, Czech Republic.
- 700 1_
- $a Pozniak, Jiří $u Thoracic and Lung Transplantation Division, Third Department of Surgery, First Faculty of Medicine, Charles University in Prague and University Hospital Motol, Prague, Czech Republic.
- 700 1_
- $a Kolařík, Jan $u Thoracic and Lung Transplantation Division, Third Department of Surgery, First Faculty of Medicine, Charles University in Prague and University Hospital Motol, Prague, Czech Republic.
- 700 1_
- $a Skallová-Fialová, Anna $u Department of Immunology, Second Faculty of Medicine and University Hospital Motol, Charles University, Prague, Czech Republic; Sotio a.s., Prague, Czech Republic.
- 700 1_
- $a Špíšek, Radek $u Department of Immunology, Second Faculty of Medicine and University Hospital Motol, Charles University, Prague, Czech Republic; Sotio a.s., Prague, Czech Republic.
- 700 1_
- $a Lischke, Robert $u Thoracic and Lung Transplantation Division, Third Department of Surgery, First Faculty of Medicine, Charles University in Prague and University Hospital Motol, Prague, Czech Republic.
- 773 0_
- $w MED00186087 $t Journal of thoracic oncology official publication of the International Association for the Study of Lung Cancer $x 1556-1380 $g Roč. 12, č. 2 (2017), s. 249-257
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/27793776 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20180515 $b ABA008
- 991 __
- $a 20180518130417 $b ABA008
- 999 __
- $a ok $b bmc $g 1300575 $s 1013791
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2017 $b 12 $c 2 $d 249-257 $e 20161025 $i 1556-1380 $m Journal of thoracic oncology $n J Thorac Oncol $x MED00186087
- LZP __
- $a Pubmed-20180515